{"id":295574,"date":"2025-11-28T00:00:00","date_gmt":"2025-11-28T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algomd0031-2023-biopharma-type-1-diabetes-current-treatment-treatment-algorithms-claims-data-analysis\/"},"modified":"2026-03-31T10:24:14","modified_gmt":"2026-03-31T10:24:14","slug":"algomd0031-2025-biopharma-type-1-diabetes-current-treatment-treatment-algorithms-claims-data-analysis-type-1-diabetes","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algomd0031-2025-biopharma-type-1-diabetes-current-treatment-treatment-algorithms-claims-data-analysis-type-1-diabetes\/","title":{"rendered":"Type 1 Diabetes &#8211; Current Treatment &#8211; Treatment Algorithms: Claims Data Analysis &#8211; Type 1 Diabetes (US)"},"content":{"rendered":"<p>Intensive insulin regimens have proven effective in delaying the progression of complications associated with untreated or poorly treated type 1 diabetes (T1D). Thus, insulin remains the cornerstone of the <abbr data-abbreviation-entity=\"5054\" title=\"type 1 diabetes\">T1D<\/abbr> market, and long-acting and rapid-acting insulins lead the patient share in the United States. The selection of branded insulin, the choice of regimen, and the order in which brands and\/or regimens are used vary. In addition, the introduction of biosimilar \/ interchangeable insulins has added complexity to the <abbr data-abbreviation-entity=\"5054\" title=\"type 1 diabetes\">T1D<\/abbr> treatment algorithm, as has the growing adoption of insulin pumps.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What patient shares do key therapies garner by line of therapy in newly diagnosed <abbr data-abbreviation-entity=\"5054\" title=\"type 1 diabetes\">T1D<\/abbr> patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed <abbr data-abbreviation-entity=\"5054\" title=\"type 1 diabetes\">T1D<\/abbr> patients?<\/li>\n<li>How have ultra-rapid-acting insulins (insulin aspart and insulin lispro-aabc) been integrated into the treatment algorithm, and what are their sources of business?<\/li>\n<li>What percentage of <abbr data-abbreviation-entity=\"5054\" title=\"type 1 diabetes\">T1D<\/abbr> patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?<\/li>\n<li>What percentage of <abbr data-abbreviation-entity=\"5054\" title=\"type 1 diabetes\">T1D<\/abbr> patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?<\/li>\n<li>What are the product-level persistence and compliance rates among drug-treated patients?<\/li>\n<\/ul>\n<p><strong>Geography:<\/strong> United States<\/p>\n<p><strong>Real-world data:<\/strong> Patient-level claims data analysis<\/p>\n<p><strong>Key drugs: <\/strong>Insulin glargine (U100), insulin degludec, insulin aspart, insulin lispro, premixed insulins<\/p>\n<div>\n<p><strong>Key analyses: <\/strong>Brand \/ therapy usage across longitudinal patient sample; Newly diagnosed patient analysis; Treatment initiation and progression; Line of therapy analysis; Combination therapy analysis; Source of business for recently treated patients; Persistency and compliance analysis; Product-level patient flow charts<\/p>\n<p><strong>Key feature:<\/strong> Dashboard featuring interactive visuals, easy navigation, and expanded analyses<\/p>\n<\/div>\n<p><strong>Product description<\/strong><\/p>\n<div>\n<p>Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:<\/p>\n<\/div>\n<div>\n<ul class=\"BulletListStyle1 SCXW2778525 BCX0 round-bullets\">\n<li>Understand patient flow between lines of therapy.<\/li>\n<li>Evaluate your brand share against competitors.<\/li>\n<li>Accurately assess your source of business.<\/li>\n<li>Quantify opportunities at different stages of the treatment algorithm.<\/li>\n<\/ul>\n<\/div>\n<p><strong>Product <\/strong><strong>enhancement<\/strong><\/p>\n<p>Treatment Algorithms: Claims Data Analysis leverages Clarivate\u2019s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.<\/p>\n","protected":false},"template":"","class_list":["post-295574","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-type-1-diabetes","biopharma-therapy-areas-type-2-diabetes","biopharma-product-current-treatment","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295574","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":4,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295574\/revisions"}],"predecessor-version":[{"id":566246,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295574\/revisions\/566246"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=295574"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}